An Early Phase 1 interventional study of DA-020 (0.1%) and DA-020 (0.2%) in Chemotherapy Induced Alopecia and Chemotherapy Side Effects, sponsored by Applied Biology, Inc.. Withdrawn at 2 sites in 2 countries. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Applied Biology, Inc. · Early Phase 1, Interventional, and Treatment
Change of protocol moved to new study
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Alopecia by Applied Biology, Inc. — 3 open to participants now, 3 under way, 2 of them phase 3. Alopecia · Applied Biology, Inc..
Among the 13 studies in Alopecia by Applied Biology, Inc., this one is one of 3 that started in 2026, is one of 2 in phase 1, and was the 12th registered.
512 studies on the registry are indexed under Alopecia; 128 are open to participants now.
Browse Alopecia studies →3 of the 13 studies in Alopecia by Applied Biology, Inc. are open now, in 2 countries. Recruiting first, the newest first:
Applied Biology, Inc. · Sites in Brazil, Italy
Ages 18–65 · Women only
Applied Biology, Inc. · Sites in Italy
Ages 18–65 · Women only
Applied Biology, Inc.
Ages 18+
By country, each count listing its studies:
Of the 76 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 48 (63%) stop at 75 or younger; 10 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 55 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 4
First in 2014; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 60 across the 9 interventional studies, 150 across the 4 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
Applied Biology, Inc. is the lead sponsor of 25 studies on the registry; 5 are open to participants now.
2 of the studies in Alopecia by Applied Biology, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06648850Phase 3Applied Biology, Inc.Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth | 2027-03-19 |
| NCT07397325Applied Biology, Inc.Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia | 2027-02-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Alopecia by Applied Biology, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pharmacokinetic Study of DA-020
A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics of DA-020
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Topical Oxymetazoline 0.1% - 7mL
Drug: DA-020 (0.1%)
Topical Oxymetazoline 0.2% - 7mL
Drug: DA-020 (0.2%)
Topical Oxymetazoline 0.5% - 7mL
Drug: DA-020 (0.5%)
DA-020 (0.1%)
DA-020 (0.2%)
DA-020 (0.5%)
Concentration of DA-020 in Serum
Determine the amount of Oxymetazoline in serum after 1 time scalp application
Time frame: Hours [0, 1, 2, 4, 8, 12, 24]
Safety and tolerability of DA-020
Determine blood pressure following a single application of DA-020
Time frame: Hours [0, 1, 2, 4, 8, 12, 24]
Plan to share: No
Ran from Apr 2026 to primary completion in Oct 2026, 6 months.
Completion moved once since we started tracking on Sep 25, 2026: Nov 2026 → Oct 2026, on Nov 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Change of protocol moved to new study
Change of protocol moved to new study
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.